← Leaderboards
Guizhi Zhu
Virginia Commonwealth University
$6,644,378
Attributed
$7,428,140
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,428,140 · 5
By mechanism
R01$4,942,726 · 3
R35$2,058,476 · 1
R21$426,938 · 1
Top collaborators
- Kristoffer Valerie2 shared
- Xiang-Yang Wang2 shared
Most similar at Virginia Commonwealth University
Same institution · by research overlap
- Devanand Sarkar$13,330,601
- Kristoffer Valerie$4,535,545
- Zhongming Zhao$10,491,216
Others in their field
Other Emerging Leaders on “Treatment Efficacy”
- Beth Baseler · Leidos Biomedical Research, Inc.$158,728,629
- Kimberly Smith · Ppd Development Lp$115,671,664
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Xinhua Li · Nano Terra, Inc.$35,520,438
- James Dale Berry · Brigham And Women'S Hospital$26,348,733
- Julie Ake · National Institute Of Allergy And Infectious Diseases$22,000,000
Research focus
Treatment EfficacyEngineeringPeptidesSafetySuccessImmunotherapyAdjuvantLymph NodesVaccinesImmunoregulationImmunityImmuneT Cell ResponseCellsTumorAntigen-Presenting CellsAntigensImmune ResponseStructureAlbuminsMouse ModelMutationNanoparticleIn Vivo
Grant awards (19)
Multivalent Small Circular mRNA Vaccines for Melanoma Combination Immunotherapy$563,293
R01 · FY2025 · CA · contact PI
Small Circular mRNA Vaccines$513,077
R01 · FY2025 · AI · contact PI
Lymph Node-Targeted Codelivery of Albumin-Binding Peptide Antigens and Di-Adjuvant for Melanoma Combination Immunotherapy$398,500
R01 · FY2025 · CA · contact PI
Nucleic acid modulators and theranostics for ADAR$381,938
R35 · FY2025 · GM · contact PI
Multivalent Small Circular mRNA Vaccines for Melanoma Combination Immunotherapy$577,293
R01 · FY2024 · CA · contact PI
Small Circular mRNA Vaccines$542,272
R01 · FY2024 · AI · contact PI
Nucleic acid modulators and theranostics for ADAR$381,938
R35 · FY2024 · GM · contact PI
Lymph Node-Targeted Codelivery of Albumin-Binding Peptide Antigens and Di-Adjuvant for Melanoma Combination Immunotherapy$378,575
R01 · FY2024 · CA · contact PI
Small circular mRNA vaccines$552,247
R01 · FY2023 · AI · contact PI
Lymph Node-Targeted Codelivery of Albumin-Binding Peptide Antigens and Di-Adjuvant for Melanoma Combination Immunotherapy$404,530
R01 · FY2023 · CA · contact PI
Nucleic acid modulators and theranostics for ADAR$381,938
R35 · FY2023 · GM · contact PI
Small circular mRNA vaccines$552,247
R01 · FY2022 · AI · contact PI
Lymph node-targeted codelivery of albumin-binding peptide antigens and di-adjuvant for melanoma combination immunotherapy$460,692
R01 · FY2022 · CA · contact PI
Nucleic Acid Modulators and Theranostics for ADAR$235,477
R35 · FY2022 · GM · contact PI
Administrative Supplement (Equipment): Nucleic acid modulators and theranostics for ADAR$175,170
R35 · FY2022 · GM · contact PI
Nucleic acid modulators and theranostics for ADAR$113,890
R35 · FY2022 · GM · contact PI
Nucleic acid modulators and theranostics for ADAR$388,125
R35 · FY2021 · GM · contact PI
Glioblastoma radioimmunotherapy$194,063
R21 · FY2021 · NS · contact PI
Glioblastoma radioimmunotherapy$232,875
R21 · FY2020 · NS · contact PI